Disease · MONDO_0006702
chronic inflammatory demyelinating polyradiculoneuropathy
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. chronic inflammatory demyelinating polyradiculoneuropathy. Diseases, record MONDO_0006702. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0006702
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
CIDP, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, chronic inflammatory demyelinating polyneuropathy, chronic inflammatory demyelinating polyradiculoneuropathy (disorder), chronic relapsing polyneuropathy
- Open Targets
Drugs19
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| HUMAN IMMUNOGLOBULIN G | CHEMBL1201599 | Approval | EMA Human Drugs | 26 | 24 | 5 | Drugs and targets | |
| EFGARTIGIMOD ALFA | CHEMBL4297551 | Protein | Approval | EMA Human Drugs | 5 | 4 | 3 | Drugs and targets |
| RITUXIMAB | CHEMBL1201576 | Antibody | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| RILIPRUBART | CHEMBL5315038 | Antibody | Phase 3 | ClinicalTrials.gov | 4 | 3 | 3 | Drugs and targets |
| EMPASIPRUBART | CHEMBL5314673 | Antibody | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| RIPERTAMAB | CHEMBL4594604 | Antibody | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| NIPOCALIMAB | CHEMBL4594310 | Antibody | Phase 3 | TTD | 2 | 1 | 1 | Drugs and targets |
| FINGOLIMOD | CHEMBL314854 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| HYALURONIDASE (HUMAN RECOMBINANT) | CHEMBL1201718 | Enzyme | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| PREDNISONE | CHEMBL635 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 19
See all 19 drugsTargets11
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| FCGRT | IgG receptor FcRn large subunit p51 | 4 | IgG receptor FcRn large subunit p51 antagonist; IgG receptor FcRn large subunit p51 inhibitor | Approval | https://conductscience.org/library/genes/2217 | Drugs and targets |
| IFNAR1 | Interferon alpha/beta receptor | 1 | Interferon alpha/beta receptor agonist | Phase 2 | https://conductscience.org/library/genes/3454 | Drugs and targets |
| IFNAR2 | Interferon alpha/beta receptor | 1 | Interferon alpha/beta receptor agonist | Phase 2 | https://conductscience.org/library/genes/3455 | Drugs and targets |
| MC2R | Adrenocorticotropic hormone receptor | 1 | Melanocortin receptor 2 agonist | Phase 2 | https://conductscience.org/library/genes/4158 | Drugs and targets |
| MS4A1 | B-lymphocyte antigen CD20 | 1 | B-lymphocyte antigen CD20 binding agent | Phase 3 | https://conductscience.org/library/genes/931 | Drugs and targets |
| NR3C1 | Glucocorticoid receptor | 1 | Glucocorticoid receptor agonist | Phase 3 | https://conductscience.org/library/genes/2908 | Drugs and targets |
| S1PR1 | Sphingosine 1-phosphate receptor | 1 | Sphingosine 1-phosphate receptor agonist; Sphingosine 1-phosphate receptor binding agent | Phase 3 | https://conductscience.org/library/genes/1901 | Drugs and targets |
| S1PR2 | Sphingosine 1-phosphate receptor | 1 | Sphingosine 1-phosphate receptor agonist; Sphingosine 1-phosphate receptor binding agent | Phase 3 | https://conductscience.org/library/genes/9294 | Drugs and targets |
| S1PR3 | Sphingosine 1-phosphate receptor | 1 | Sphingosine 1-phosphate receptor agonist; Sphingosine 1-phosphate receptor binding agent | Phase 3 | https://conductscience.org/library/genes/1903 | Drugs and targets |
| S1PR4 | Sphingosine 1-phosphate receptor | 1 | Sphingosine 1-phosphate receptor agonist; Sphingosine 1-phosphate receptor binding agent | Phase 3 | https://conductscience.org/library/genes/8698 | Drugs and targets |
1 to 10 of 11
See all 11 targetsTrials33
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 17 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04281472 | A Study to Assess the Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves) | Phase 2 | 322 | 2024-08-20 | Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | EFGARTIGIMOD ALFA | Its record names the disease | ClinicalTrials.gov |
| NCT02638207 | Study to Evaluate Safety and Efficacy of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly (Radiculo) Neuropathy | Phase 3 | 142 | 2021-02-16 | Chronic Inflammatory Demyelinating Poly(Radiculo)Neuropathy | HUMAN IMMUNOGLOBULIN G | Its record names the disease | ClinicalTrials.gov |
| NCT02549170 | A Study of HyQvia and Gammagard Liquid (Kiovig) in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | Phase 3 | 138 | 2023-05-24 | Chronic Inflammatory Demyelinating Polyradiculoneuropathy | HUMAN IMMUNOGLOBULIN G | Its record names the disease | ClinicalTrials.gov |
| NCT01625182 | Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients. | Phase 3 | 106 | 2017-09-19 | Chronic Inflammatory Demyelinating Polyradiculoneuropathy | FINGOLIMOD | Its record names the disease | ClinicalTrials.gov |
| NCT02027701 | Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | Phase 3 | 82 | 2018-10-02 | Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | HUMAN IMMUNOGLOBULIN G | Its record names the disease | ClinicalTrials.gov |
| NCT00278629 | Hematopoietic Stem Cell Transplantation in Chronic Inflammatory Demyelinating Polyneuropathy | Phase 2 | 80 | 2020-07-23 | Chronic Inflammatory Demyelinating Polyneuropathy | CYCLOPHOSPHAMIDE, RITUXIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT03861481 | A Study to Assess the Efficacy, Safety and Tolerability of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy | Phase 2 | 34 | 2022-04-04 | Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | ROZANOLIXIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT05084053 | A Study of TAK-771 in Japanese Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) and Multifocal Motor Neuropathy (MMN) | Phase 3 | 26 | 2025-03-18 | Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), Multifocal Motor Neuropathy (MMN) | HYALURONIDASE (HUMAN RECOMBINANT) | Its record names the disease | ClinicalTrials.gov |
| NCT04051944 | A Study to Assess Long-term Safety, Tolerability and Efficacy of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy | Phase 2 | 21 | 2022-11-03 | Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | ROZANOLIXIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02465359 | Subcutaneous Immunoglobulin for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | Not applicable | 15 | 2024-10-08 | Chronic Inflammatory Demyelinating Polyneuropathy | HUMAN IMMUNOGLOBULIN G | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 33
See all 33 trialsComparisons in its trials7
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Stage B: Efgartigimod PH20 SC vs Stage B: Placebo PH20 SC: Stage B: Number of Participants With Improved Functional Level Compared to Stage B Baseline | 50 of 111 | 40 of 110 | 221 | NCT04281472 | Trial comparisons |
| Epoch 1: Placebo With rHuPH20 vs Epoch 1: HYQVIA/HyQvia: Epoch 1: Number of Participants Who Develop Binding and/or Neutralizing Antibodies to Recombinant Human Hyaluronidase (rHuPH20) | 7 of 70 | 1 of 62 | 132 | NCT02549170 | Trial comparisons |
| Rozanolixizumab vs Placebo: deaths from any cause | 0 of 17 | 0 of 17 | 34 | NCT03861481 | Trial comparisons |
| Rozanolixizumab vs Placebo: serious adverse events | 2 of 17 | 0 of 17 | 34 | NCT03861481 | Trial comparisons |
| Rozanolixizumab (Newly Treated) vs Rozanolixizumab (Previously Treated): Number of Participants With Treatment-emergent Adverse Event (TEAEs) | 10 of 11 | 10 of 10 | 21 | NCT04051944 | Trial comparisons |
| Rozanolixizumab (Newly Treated) vs Rozanolixizumab (Previously Treated): deaths from any cause | 0 of 11 | 0 of 10 | 21 | NCT04051944 | Trial comparisons |
| Rozanolixizumab (Newly Treated) vs Rozanolixizumab (Previously Treated): serious adverse events | 2 of 11 | 2 of 10 | 21 | NCT04051944 | Trial comparisons |
Papers from its trials13
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
| PMID | Listed as | Trials listing it | Source |
|---|---|---|---|
| 32594300 | RESULT | 1 | PubMed |
| 42578463 | DERIVED | 1 | PubMed |
| 39658326 | DERIVED | 1 | PubMed |
| 39304241 | DERIVED | 1 | PubMed |
| 38729747 | DERIVED | 2 | PubMed |
| 38729746 | DERIVED | 1 | PubMed |
| 38353301 | DERIVED | 2 | PubMed |
| 38205888 | DERIVED | 1 | PubMed |
| 37899433 | DERIVED | 1 | PubMed |
| 37378806 | DERIVED | 1 | PubMed |
1 to 10 of 13
See all 13 papers from its trialsData dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0006702
GET https://conductscience.org/api/diseases/v1/MONDO_0006702/trials?page=2